Base to Base biotech podcast 3: Nanoparticles and Duchenne muscular dystrophy

Interview timestamps:

02:20 Satellos

26:00 EVŌQ Nano

Antibiotic-resistant infections are a top 10 global health threat demanding urgent innovation.

A US-based nanotech company, EVŌQ Nano, has developed a novel nanoparticle that destroys bacteria from the inside – without triggering antimicrobial resistance (AMR).

The nanoparticle is already in development for an inhaled therapeutic for Cystic Fibrosis patients, as well as for antimicrobial medical devices and treatment of the surface of textiles. It is also being earmarked for applications in energy and agriculture.

The company’s multi-patented, high-volume laser nanofabrication process creates uniform, sub-10nm nanoparticles with di ...